Categories Earnings, Health Care

BioCryst Pharmaceuticals (BCRX) Q4 2019 Earnings Snapshot

— BioCryst Pharmaceuticals (NASDAQ: BCRX) reported a loss of $0.02 per share for the fourth quarter of 2019 vs. expected loss of $0.26 per share.

— Revenue was $39.7 million vs. $2.7 million in the fourth quarter of 2018 and targeted revenue of $9.88 million.

Earnings Update by AlphaStreet

— R&D expenses increased to $26.8 million from $23.4 million in the prior-year quarter.

— For full-year 2020, operating cash use is expected to be in the range of $125 million to $150 million and operating expenses are estimated to be between $135 million and $160 million.

— On February 18, 2020, the company announced that the U.S. Food and Drug Administration (FDA) had accepted and filed its new drug application (NDA) for the approval of oral, once-daily berotralstat (BCX7353) for the prevention of hereditary angioedema (HAE) attacks.

— BioCryst expects Japanese Pharmaceuticals and Medical Devices Agency (PMDA) to approve its berotralstat drug for the prophylactic treatment of HAE in the second half of 2020.

— BCRX stock rose about 7% in the pre-market trading session.

We’re on Apple News! Follow us to receive the latest stock market, earnings and financial news at your fingertips

Most Popular

Micron Technology (MU) Q3 Earnings: Key financials and quarterly highlights

Micron Technology Inc. (NASDAQ: MU) reported third quarter 2022 earnings results today. Revenue increased 16% year-over-year to $8.64 billion. GAAP net income was $2.63 billion, or $2.34 per share, compared

Constellation Brands (STZ): Earnings beat and share structure revamp put brewer in the spotlight

Shares of Constellation Brands Inc. (NYSE: STZ) were down 4% on Thursday despite the company beating expectations on its first quarter 2023 earnings results. The stock has dropped 7% year-to-date.

Infographic: Key highlights from Constellation Brands (STZ) Q1 2023 earnings results

Constellation Brands, Inc. (NYSE: STZ) reported first quarter 2023 earnings results today. Net sales increased 17% year-over-year to $2.3 billion. Net income attributable to CBI was $390 million, or $2.06

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top